K
Kansas Medical Clinic | KMC Research Center
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Relamorelin
IW-3718
Xifaxan
SPD476
NG101
Vonoprazan
Retinoid
Obeticholic Acid
Lebrikizumab
Vancomycin
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
1 of 16 total trials
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
I
N
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems